BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7694371)

  • 21. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
    Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.
    Elias L; Stock-Novack D; Head DR; Grever MR; Weick JK; Chapman RA; Godwin JE; Metz EN; Appelbaum FR
    Leukemia; 1993 Mar; 7(3):361-5. PubMed ID: 7680398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
    Tobinai K; Watanabe T; Ogura M; Morishima Y; Ogawa Y; Ishizawa K; Minami H; Utsunomiya A; Taniwaki M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Seriu T; Hotta T
    J Clin Oncol; 2006 Jan; 24(1):174-80. PubMed ID: 16330664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
    Binet JL
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):5-7. PubMed ID: 7685518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
    Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
    Pillay GS; Wood L; Jacobs P
    S Afr Med J; 1996 Aug; 86(8):949-51. PubMed ID: 8823419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
    Keating MJ; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs CC; Freireich EJ; McCredie KB
    J Clin Oncol; 1991 Jan; 9(1):44-9. PubMed ID: 1702145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
    Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E
    Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Kasamon YL; Flinn IW; Grever MR; Diehl LF; Garrett-Mayer E; Goodman SN; Lucas MS; Byrd JC
    Clin Cancer Res; 2005 Dec; 11(23):8413-7. PubMed ID: 16322303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
    De Rossi G; Mauro FR; Caruso R; Monarca B; Mandelli F
    Haematologica; 1993; 78(3):167-71. PubMed ID: 8375746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
    Chun HG; Leyland-Jones B; Cheson BD
    J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
    Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Keating MJ
    Leukemia; 1995 Jun; 9(6):943-5. PubMed ID: 7596181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
    Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
    Decaudin D; Bosq J; Tertian G; Nedellec G; Bennaceur A; Venuat AM; Bayle C; Carde P; Bendahmane B; Hayat M; Munck JN
    J Clin Oncol; 1998 Feb; 16(2):579-83. PubMed ID: 9469344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
    Huang HQ; Jiang WQ; Peng YL; Xia ZJ; Li YH; Li XB; Lin TY; Sun XF; Guan ZZ
    Ai Zheng; 2004 Apr; 23(4):448-51. PubMed ID: 15087037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.